factually
Index/Organizations/Prime Therapeutics

Prime Therapeutics

American pharmacy benefit management company

Fact-Checks

2 results
Jan 14, 2026

Which oral GLP‑1 and multi‑agonist drugs are nearest FDA approval and how might their costs differ from injectables?

Two oral GLP‑1 pills are effectively already at the finish line: Novo Nordisk’s oral semaglutide (Wegovy pill) received FDA approval in late 2025 with a U.S. launch planned for early January 2026, and...

Dec 5, 2025

Are there clinical trial results comparing gelatide to approved GLP-1 or peptide obesity drugs?

There are many recent clinical trials and reviews comparing drugs in the GLP-1 class to one another, and a vigorous pipeline of non‑GLP-1 obesity agents is advancing — but the provided sources do not ...